Status:
UNKNOWN
The Role of the Immune and Inflammatory Systems in Hypertension
Lead Sponsor:
University of Glasgow
Collaborating Sponsors:
European Research Council
Conditions:
Hypertension
Inflammation
Eligibility:
All Genders
18-55 years
Brief Summary
To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.
Detailed Description
Experimental data show the presence of immune and inflammatory systems dysregulation in hypertension. Understanding of the inflammatory and immune nature of hypertension is currently based on studies ...
Eligibility Criteria
Inclusion
- Age between 18-55 years
- Cases: Office blood pressure ≥140 and ≥90
- Controls: Office blood pressure \<140 and \<90 and age, sex and BMI matching to cases
Exclusion
- Age \>55 years old;
- Secondary hypertension (including e.g. adrenal tumours, pheochromocytoma, renal artery stenosis; thyroid disease)
- Acute inflammatory disorders incl. flu, rhinitis, sinusitis etc. within 3 weeks;
- hospitalization within the past 3 months;
- Life expectancy of \< 3 years;
- History of alcohol/substance abuse
- Inflammatory conditions e.g. Allergic disorders; chronic infections, COPD, tuberculosis; hepatitis B or C; pneumonitis, bronchiectasis; pericardial or pleural effusion, ascites; liver disease;
- Chronic inflammatory/autoimmune conditions such (e.g. SLE, rheumatoid arthritis, ulcerative colitis/Crohn's disease; non-basal cell malignancy or myelo- or lymphoproliferative disease within the past 5 years; known HIV+; Immunizations (3 months); pulmonary hypertension;
- Pregnancy, nursing;
- History of symptomatic coronary artery disease (events) or heart failure;
- BMI\>40,
- diabetes/glucose intolerance (fasting glucose, HbA1; testing, glucose challenge where indicated);
- Known albuminuria/microalbuminuria;
- GFR\<60mL/min/1.73m2.
- Any chronic concurrent treatment: Use of systemic or local steroids/immunosuppressive agents (within 6 months) of the inclusion; Current (within past 3 months) use of anti-hypertensive medication;
- Major depressive illness or other psychiatric conditions.
- Participants who decline participation in the study or who are unable to provide informed consent
Key Trial Info
Start Date :
May 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04015635
Start Date
May 7 2019
End Date
September 1 2021
Last Update
May 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Facility
Glasgow, City of Glasgow, United Kingdom, G51 4LB